Recruiting

IAb Screening

Sponsor:

Institut de Recherches Cliniques de Montreal

Code:

NCT07322380

Conditions

Type 1 Diabetes (T1D)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Centralized Monitoring Approach

Decentralized Monitoring Approach

Study Details

Brief summary:

The aim of this study will be to evaluate the feasibility of an autoantibody-based type 1 diabetes screening program for first degree relatives of people living with type 1 diabetes within the province of Quebec. Feasibility of follow-up strategies of "at-risk" individuals will also be assessed.

This project will be divided into two phases, with the aim to evaluate:

1. The feasibility of a IAb (islet antibody)-based screening process for first degree relatives of people living with type 1 diabetes (T1D).
2. The feasibility of two approaches for follow-up monitoring in case of positive screening: centralized (within the organization) and decentralized approach (relying on individuals' healthcare providers), in the Quebec province setting.

Participants will come to the laboratory for blood sample collection, medical history and genetic risk score assessment, as well as anthropometric and cutaneous advanced glycated end (AGE) products measurements. A series of questionnaires will be completed.

After screening results are obtained (i.e., presence or absence of IAbs), a virtual visit will be conducted to communicate results to participants.

A positive result for IAb will warrant a second test for confirmation , using WBD within 3 months of initial screening.

After IAb positivity confirmation, participants will be invited to participate in phase 2 of this project (monitoring). Participants will be given the opportunity to select either a centralized or decentralized path for study monitoring.

Follow-up will be dependent of the stage of T1D:

  • Participants in pre-stage 1 or stage 1 (2 or more positive IAbs without dysglycemia) T1D will receive a follow-up phone call six months after the initial screening.
  • Participants in stage 2 (2 or more positive IAbs with dysglycemia) will be contacted one month after screening.

Conditions

Type 1 Diabetes (T1D)

Study ID

NCT07322380

Start date

Sep 1, 2026

Status verified date

Oct, 2026

Completion date

Mar 31, 2028

Anticipated

Primary completion date

Feb 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Males and females ≥18 years old living in the Québec province
  • Having a FDR living with T1D (parents, siblings or offspring)
  • Willing to adhere to follow-up care if screened positive

Exclusion Criteria:

  • Having a diagnosis of T1D
  • Pregnancy (ongoing or current attempt to become pregnant)
  • Current or future expected use of glucocorticoid medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®) or any systemic immunosuppressive agents
  • Planned or recent (< 6 weeks) monoclonal antibodies treatment, immunoglobulin perfusions or plasmapheresis.
  • Other serious medical illness likely to interfere with study participation or with the ability to complete the study by the judgment of the investigator

Study Design

Enrollment

1000 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Screening

Interventions and Outcome Measures

Arms

active comparator: Centralized approach

Centralized approach managed and coordinated within the BETTER group based at IRCM (Montreal, Quebec), with standardized processes and integrated care pathways. In this approach, scheduling processes and data collection (clinical visits, laboratory analysis, questionnaires) will be handled by the research team. Participants' healthcare professional will be notified (by postal service and/or email if available)

active comparator: Decentralized approach

In this approach, participants will be monitored by their preferred HCP according to consensus-based guidelines for monitoring pre-clinical T1D which will be communicated to both participants and HCPs. Therefore, follow-up and monitoring will be at the discretion of the HCP. However, regular contacts by the research team according to T1D stages will ensure the actual follow-up received.

Interventions

Centralized Monitoring Approach

A semi-annual clinical visit (either by medical or trained staff) will be conducted to collect various data: IAb assessment, HbA1c measure, fasting blood glucose, glucose monitoring and information about eating habits, mental health, menstrual cycle, physical activity.

Decentralized Monitoring Approach

Monitored by the participant's preferred local Healthcare Provider (HCP) according to consensus-based guidelines for pre-clinical T1D. The research team does not conduct direct clinical visits; instead, the research team conducts semi-annual phone calls (and initial 1-month or 6-month check-ins depending on T1D stage) to confirm that appropriate HCP follow-up is ongoing, document any clinical assessments conducted by the HCP, and collect the results of those investigations.

Primary outcome measure

  • Feasibility of screening and monitoring outcomes [ Time Frame: Through study completion for positive screened participants: 3 years ]

Central Contacts and Locations

Central contacts

Maha Lebbar, M.D.

maha.lebbar@ircm.qc.ca

Locations

Institut de recherches cliniques de Montréal

Recruiting

Montreal, Quebec, Canada, H2W 1R7

Contacts

More Information

Sponsor

Institut de Recherches Cliniques de Montreal

Last update posted

Nov 17, 2026

Last verified

Oct, 2026

Keywords

  • screening
  • type 1 diabetes

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by Institut de Recherches Cliniques de Montreal on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.